SELECT * FROM `stock_list` WHERE `symbol` = "SYRS" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='SYRS' AND exchange = 'NAS' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "SYRS" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 SYRS (Syros Pharmaceuticals) Growth Rank
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Growth Rank

Syros Pharmaceuticals (Syros Pharmaceuticals) Growth Rank : 2 (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Growth Rank?

Syros Pharmaceuticals has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Syros Pharmaceuticals's Growth Rank

For the Biotechnology subindustry, Syros Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syros Pharmaceuticals's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Growth Rank distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Growth Rank falls into.


Syros Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Syros Pharmaceuticals (Syros Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Growth Rank
Comparable Companies
TPST CLNN SABS CRVS KNTE RANI AFMD CTCX CRDF KRON OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0S90:Germany 0S90:Germany
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Website
https://www.syros.com
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is mainly involved in the segments of pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States.
Executives
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
David Roth officer: Chief Medical Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Eric R Olson officer: Chief Scientific Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson director ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Jason Haas officer: Chief Financial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley officer: Chief Commercial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Kristin Stephens officer: Chief Development Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Richard A Young director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn officer: Chief Business Officer C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Arch Venture Fund Vii, L.p. 10 percent owner 8755 W HIGGINS, SUITE 1025, Chicago IL 60631
Alice Tsang Shaw director MASSACHUSETTS GENERAL HOSPITAL, 55 FRUIT ST., #148, BOSTON MA 02114